In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. 

Fierce Biotech's Annalee Armstrong and Gabrielle Masson take you behind the scenes to explore the meticulous selection process and share interesting highlights from this year’s honorees. 

To learn more about the topics in this episode: 
Introducing Fierce Biotech's 2024 Fierce 15
Fierce Biotech's Gabrielle Masson presents Fierce 15 at NYSE
Fierce 15: Where are they now?

In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. 
Fierce Biotech's Annalee Armstrong and Gabrielle Masson take you behind the scenes to explore the meticulous selection process and share interesting highlights from this year’s honorees. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/special-reports/introducing-fierce-biotechs-2024-fierce-15">Introducing Fierce Biotech's 2024 Fierce 15</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotechs-gabrielle-masson-presents-fierce-15-nyse">Fierce Biotech's Gabrielle Masson presents Fierce 15 at NYSE</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-15-where-are-they-now-0">Fierce 15: Where are they now?</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

A closer look at Fierce Biotech's Fierce 15

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1 battle between Novo Nordisk and Eli Lilly and new leadership at Sarepta and Sanofi, it feels like the opportunities and challenges for biopharma have never been greater.

In this week’s episode of "The Top Line," Fierce Pharma Senior Editor Fraiser Kansteiner and Fierce Biotech Senior Editor James Waldron share their takeaways from another whirlwind season of earnings calls. Alongside a Q2 scorecard breakdown, the Fierce editors discuss how several new CEOs are finding their footing, which drugs appear poised to cross the $1 billion sales threshold in 2026 and more.

To learn more about the topics in this episode: 
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas 
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow
Sarepta’s new CEO Michael Severino faces critical milestones to prove growth

Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1 battle between Novo Nordisk and Eli Lilly and new leadership at Sarepta and Sanofi, it feels like the opportunities and challenges for biopharma have never been greater.
In this week&rsquo;s episode of "The Top Line," Fierce Pharma Senior Editor Fraiser Kansteiner and Fierce Biotech Senior Editor James Waldron share their takeaways from another whirlwind season of earnings calls. Alongside a Q2 scorecard breakdown, the Fierce editors discuss how several new CEOs are finding their footing, which drugs appear poised to cross the $1 billion sales threshold in 2026 and more.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/biopharma-saw-q2-sales-boom-led-lilly-sanofi-regeneron-and-astellas" data-processed-url="true">Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas</a>&nbsp;</li>
<li><a href="https://www.fiercebiotech.com/biotech/sanofis-new-ceo-looking-deeply-late-stage-pipeline-clinical-clearout-continues" data-processed-url="true">Sanofi&rsquo;s new CEO &lsquo;looking deeply&rsquo; at late-stage pipeline as clinical clearout continues</a></li>
<li><a href="https://www.fiercepharma.com/pharma/novo-ceo-has-no-doubt-eventual-share-price-correction-wegovy-pill-continues-wow" data-processed-url="true">Novo CEO has 'no doubt' on eventual share price recovery as Wegovy pill continues to wow</a></li>
<li><a href="https://www.fiercepharma.com/pharma/sarepta-new-ceo-michael-severino-faces-critical-tests-prove-growth" data-processed-url="true">Sarepta&rsquo;s new CEO Michael Severino faces critical milestones to prove growth</a></li>
</ul>

 What did we learn from Big Pharma’s Q2 results?

Consumerization is changing how patients engage with healthcare, and pharma companies may need to rethink how they approach awareness, diagnosis and commercialization.

In this sponsored episode of The Top Line, host Irena Luo is joined by Rachel Stoll, Managing Partner, Growth & Innovation at Princeton10, and Kevin Nalty, Vice President of Strategy at Princeton10, to discuss how evolving patient behaviors are reshaping the healthcare journey. Together, they explore the impact of GLP-1s, telemedicine, AI, wellness technologies and other low-friction healthcare experiences that are raising expectations for convenience and accessibility.

The conversation examines emerging gaps between health awareness and clinical diagnosis, the role of wellness tools and health data, and why some patients delay or avoid care altogether. The guests also discuss opportunities for pharma brands to rethink disease awareness, improve navigation to diagnosis and treatment, and borrow engagement strategies from successful consumer platforms that encourage long-term behavior change.

Listen to hear practical insights on how brand teams can adapt their commercial strategies, identify hidden friction points and better meet the needs of today's healthcare consumer.

Consumerization is changing how patients engage with healthcare, and pharma companies may need to rethink how they approach awareness, diagnosis and commercialization.
In this sponsored episode of The Top Line, host Irena Luo is joined by Rachel Stoll, Managing Partner, Growth &amp; Innovation at Princeton10, and Kevin Nalty, Vice President of Strategy at Princeton10, to discuss how evolving patient behaviors are reshaping the healthcare journey. Together, they explore the impact of GLP-1s, telemedicine, AI, wellness technologies and other low-friction healthcare experiences that are raising expectations for convenience and accessibility.
The conversation examines emerging gaps between health awareness and clinical diagnosis, the role of wellness tools and health data, and why some patients delay or avoid care altogether. The guests also discuss opportunities for pharma brands to rethink disease awareness, improve navigation to diagnosis and treatment, and borrow engagement strategies from successful consumer platforms that encourage long-term behavior change.
Listen to hear practical insights on how brand teams can adapt their commercial strategies, identify hidden friction points and better meet the needs of today's healthcare consumer.

How consumerization is reshaping pharma marketing (Sponsored)

Having spent 14 years building out its capacity, Regeneron Genetics Center—the genomic research branch of the Tarrytown, New York-based pharma—is a pro when it comes to the sort of target validation work central to the field today. Now, as RGC continues the massive expansion of its genetic database, the center’s unique ability to interpret that trove of data could give it an edge in the age of AI-powered drug development.

In this week’s episode of "The Top Line," Fierce’s Fraiser Kansteiner sits down with Andy Deubler, chief business and administrative officer at Regeneron Genetics Center, to discuss the role RGC plays in the larger Regeneron model, as well as where the center could be headed as drug development pushes into new technological frontiers. Aside from the data interpretation advantage RGC believes it holds in the AI era, Deubler also discusses how the unit’s ongoing genetic research has helped deliver recent breakthroughs like the hearing loss gene therapy Otarmeni.

To learn more about the topics in this episode: 
Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval 
J. Craig Venter launches genomics startup designed to boost diagnostic insights
Genomics inks partnership deal with Greywolf to assess gene datasets
How a new tool for large-scale gene editing could power novel genetic medicines

 

In global life sciences, insight isn’t the problem—execution is. 

Disconnected dashboards, siloed teams and fragmented workflows make it harder to act—consistently, compliantly and at scale. 

ZAIDYN by ZS closes that gap. 

ZAIDYN is the Life Sciences Intelligence Platform that embeds intelligence in the flow of work, based on domain expertise and agentic AI across commercial, medical, patient and content work.

Trusted by more than 150 life sciences organizations across over 100 countries, ZAIDYN is built for global scale, regulatory compliance and trusted AI—so teams act together across brands, markets and channels. 

ZAIDYN. Move beyond reporting to intelligent action. 

Learn more at ZAIDYN.ai

Having spent 14 years building out its capacity, Regeneron Genetics Center&mdash;the genomic research branch of the Tarrytown, New York-based pharma&mdash;is a pro when it comes to the sort of target validation work central to the field today. Now, as RGC continues the massive expansion of its genetic database, the center&rsquo;s unique ability to interpret that trove of data could give it an edge in the age of AI-powered drug development.
In this week&rsquo;s episode of "The Top Line," Fierce&rsquo;s Fraiser Kansteiner sits down with Andy Deubler, chief business and administrative officer at Regeneron Genetics Center, to discuss the role RGC plays in the larger Regeneron model, as well as where the center could be headed as drug development pushes into new technological frontiers. Aside from the data interpretation advantage RGC believes it holds in the AI era, Deubler also discusses how the unit&rsquo;s ongoing genetic research has helped deliver recent breakthroughs like the hearing loss gene therapy Otarmeni.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/regeneron-ushers-new-genetic-medicine-era-groundbreaking-gene-therapy-approval" data-processed-url="true">Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval</a>&nbsp;</li>
<li><a href="https://www.fiercebiotech.com/medtech/j-craig-venter-launches-genomics-startup-designed-boost-diagnostic-insights" data-processed-url="true">J. Craig Venter launches genomics startup designed to boost diagnostic insights</a></li>
<li><a href="https://www.fiercebiotech.com/medtech/genomics-inks-partnership-deal-greywolf-assess-gene-datasets" data-processed-url="true">Genomics inks partnership deal with Greywolf to assess gene datasets</a></li>
<li><a href="https://www.fiercebiotech.com/research/new-tool-large-scale-gene-editing-could-power-next-gen-genetic-medicines" data-processed-url="true">How a new tool for large-scale gene editing could power novel genetic medicines</a></li>
</ul>
&nbsp;
In global life sciences, insight isn&rsquo;t the problem&mdash;execution is.&nbsp;
Disconnected dashboards, siloed teams and fragmented workflows make it harder to act&mdash;consistently, compliantly and at scale.&nbsp;
ZAIDYN by ZS closes that gap.&nbsp;
ZAIDYN is the Life Sciences Intelligence Platform that embeds intelligence in the flow of work, based on domain expertise and agentic AI across commercial, medical, patient and content work.
Trusted by&nbsp;more than&nbsp;150 life sciences organizations across&nbsp;over&nbsp;100&nbsp;countries,&nbsp;ZAIDYN is&nbsp;built&nbsp;for global scale, regulatory&nbsp;compliance&nbsp;and trusted AI&mdash;so teams act together&nbsp;across brands,&nbsp;markets&nbsp;and channels.&nbsp;
ZAIDYN. Move beyond reporting to intelligent action.&nbsp;
Learn more&nbsp;at&nbsp;ZAIDYN.ai

A closer look at Fierce Biotech's Fierce 15

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips